Clinical Trial: Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07424157) titled 'Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products' on Feb. 13.

Brief Summary: Subjects exposed to gene therapy products (GTPs) may be at risk for delayed or long-term adverse events. This is a long-term follow-up (LTFU) protocol designed to evaluate the long-term safety of Seattle Children's Therapeutics (SCTx) GTPs and incorporates in monitoring guidance from the U.S. Food and Drug Administration (FDA). Subjects will be followed for up to 15 years starting from the date of the most recent infusion of an SCTx GTP. Subjects planning to receive, or who have received, at least one infusi...